Dr. Redell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6701 Fannin St
Houston, TX 77030Phone+1 832-822-4240Fax+1 832-825-4247
Education & Training
- Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2001 - 2004
- Baylor College of Medicine (Houston)Residency, Pediatrics, 1998 - 2001
- University of Washington School of MedicineClass of 1998
- University of WashingtonPh.D., Pharmacology, 1996
- Brown UniversitySc.B., Neural Science, 1988
Certifications & Licensure
- TX State Medical License 2002 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Chief Fellow Pediatric Hematology-Oncology, Baylor College of Medicine, 2003
Clinical Trials
- Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia Start of enrollment: 2012 Sep 01
- Biomarkers in Young Patients With Acute Myeloid Leukemia Start of enrollment: 2009 Sep 01
- Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia Start of enrollment: 2010 May 01
- Join now to see all
Publications & Presentations
PubMed
- 55 citationsDOT1L Inhibition Sensitizes MLL-Rearranged AML to ChemotherapyWei Liu, Lisheng Deng, Yongcheng Song, Michele S. Redell
Plos One. 2014-05-23 - 17 citationsVenetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience.Adriana Trabal, Amber Gibson, Jiasen He, David McCall, Michael Roth
Cancers. 2023-03-26 - 83 citationsPharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemiaZizhen Feng, Yuan Yao, Chao Zhou, Fengju Chen, Fangrui Wu
Journal of Hematology & Oncology. 2016-03-12
Journal Articles
- Drug Targeting of NR4A Nuclear Receptors for Treatment of Acute Myeloid LeukemiaMichele Redell, MD, Nature
- Ligand-induced Stat3 signaling increases at relapse and is associated with outcome in pediatric AML: A Report from the Children’s Oncology GroupStevens, A.M., Ruiz, M.J, Gerbing, R.B., Alonzo, T.A., Gamis, A. and Redell, M.S., Haematologica, 1/1/2015
- Rhodium(II) proximity-labeling identifies a novel target site on STAT3 for inhibitors with potent anti-leukemia activityMinus, M., Liu, W., Vohidov, F., Kasembeli, M., Long, X., Krueger, M., Stevens, A., Kolosov, M., Sison, E., Tweardy, D., Redell, M. and Ball, Z., Angew. Chemie., 1/1/2015
- Join now to see all
Abstracts/Posters
- Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia in the Contemporary EraMichele Redell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid LeukemiaMichele Redell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Inhibition of BMP-Smad Pathway Reduces Leukemic Stemness in Pediatric AMLMichele Redell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Grant Support
- STAT3 Isoforms In Maturation And Survival Of Normal And Malignant Myeloid CellsNational Heart, Lung, And Blood Institute2008–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: